Boehringer brings early data for GLP-1 receptor showing almost 15% weight loss after 46 weeks
Boehringer Ingelheim and Zealand Pharma released Phase II data on their weight loss candidate, a glucagon and GLP-1 receptor agonist called BI 456906, playing catch-up with leaders like Novo Nordisk and Eli Lilly as the obesity market balloons.
The data met its primary endpoint in the dose-finding trial: up to 14.9% weight loss after 46 weeks using the planned maintenance dose. This study enrolled patients who are living with obesity or are overweight without type 2 diabetes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.